[go: up one dir, main page]

WO2008058192A3 - Heterodimers of glutamic acid - Google Patents

Heterodimers of glutamic acid Download PDF

Info

Publication number
WO2008058192A3
WO2008058192A3 PCT/US2007/083934 US2007083934W WO2008058192A3 WO 2008058192 A3 WO2008058192 A3 WO 2008058192A3 US 2007083934 W US2007083934 W US 2007083934W WO 2008058192 A3 WO2008058192 A3 WO 2008058192A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
heteroaryl
alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/083934
Other languages
French (fr)
Other versions
WO2008058192A2 (en
Inventor
John W Babich
Craig N Zimmerman
Kevin P Maresca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Insight Pharmaceuticals Inc
Original Assignee
Molecular Insight Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39365345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008058192(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to ES07844938.6T priority Critical patent/ES2547481T3/en
Priority to AU2007316391A priority patent/AU2007316391B2/en
Priority to JP2009536459A priority patent/JP5606737B2/en
Priority to EP18150494.5A priority patent/EP3335736B1/en
Priority to CN200780049490.2A priority patent/CN101778910B/en
Priority to EP07844938.6A priority patent/EP2097111B1/en
Priority to CA2669127A priority patent/CA2669127C/en
Application filed by Molecular Insight Pharmaceuticals Inc filed Critical Molecular Insight Pharmaceuticals Inc
Priority to SI200731686T priority patent/SI2097111T1/en
Priority to PL07844938T priority patent/PL2097111T3/en
Priority to EP21208033.7A priority patent/EP4023624A1/en
Priority to EP19214298.2A priority patent/EP3699162B1/en
Priority to BRPI0718700A priority patent/BRPI0718700B8/en
Priority to DK07844938.6T priority patent/DK2097111T3/en
Publication of WO2008058192A2 publication Critical patent/WO2008058192A2/en
Publication of WO2008058192A3 publication Critical patent/WO2008058192A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nuclear Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Compounds of Formula (Ia), wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or -NR'R', Q is C(O), O, NR', S, S(O)2, C(O)2 (CH2)p Y is C(O), O, NR', S, S(O)2, C(O)2 (CH2)p Z is H or C1-C4 alkyl, R' is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, -NR'R' or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.
PCT/US2007/083934 2006-11-08 2007-11-07 Heterodimers of glutamic acid Ceased WO2008058192A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
DK07844938.6T DK2097111T3 (en) 2006-11-08 2007-11-07 Heterodimers of glutamic acid
SI200731686T SI2097111T1 (en) 2006-11-08 2007-11-07 Heterodimers of glutamic acid
JP2009536459A JP5606737B2 (en) 2006-11-08 2007-11-07 Glutamic acid heterodimer
EP18150494.5A EP3335736B1 (en) 2006-11-08 2007-11-07 Heterodimers of glutamic acid
CN200780049490.2A CN101778910B (en) 2006-11-08 2007-11-07 Heterodimers of glutamic acid
EP07844938.6A EP2097111B1 (en) 2006-11-08 2007-11-07 Heterodimers of glutamic acid
CA2669127A CA2669127C (en) 2006-11-08 2007-11-07 Heterodimers of glutamic acid
ES07844938.6T ES2547481T3 (en) 2006-11-08 2007-11-07 Heterodimers of glutamic acid
PL07844938T PL2097111T3 (en) 2006-11-08 2007-11-07 Heterodimers of glutamic acid
EP21208033.7A EP4023624A1 (en) 2006-11-08 2007-11-07 Heterodimers of glutamic acid
AU2007316391A AU2007316391B2 (en) 2006-11-08 2007-11-07 Heterodimers of glutamic acid
EP19214298.2A EP3699162B1 (en) 2006-11-08 2007-11-07 Heterodimers of glutamic acid
BRPI0718700A BRPI0718700B8 (en) 2006-11-08 2007-11-07 Glutamic acid heterodimers, and kit

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US85749006P 2006-11-08 2006-11-08
US60/857,490 2006-11-08
US87867807P 2007-01-05 2007-01-05
US60/878,678 2007-01-05

Publications (2)

Publication Number Publication Date
WO2008058192A2 WO2008058192A2 (en) 2008-05-15
WO2008058192A3 true WO2008058192A3 (en) 2008-09-12

Family

ID=39365345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/083934 Ceased WO2008058192A2 (en) 2006-11-08 2007-11-07 Heterodimers of glutamic acid

Country Status (16)

Country Link
US (11) US20080193381A1 (en)
EP (5) EP4023624A1 (en)
JP (2) JP5606737B2 (en)
CN (2) CN103922998A (en)
BR (1) BRPI0718700B8 (en)
CA (1) CA2669127C (en)
CY (1) CY1116610T1 (en)
DK (1) DK2097111T3 (en)
ES (4) ES2547481T3 (en)
HK (1) HK1200164A1 (en)
HU (3) HUE039199T2 (en)
PL (3) PL2942065T3 (en)
PT (2) PT3699162T (en)
SI (1) SI2097111T1 (en)
TW (1) TWI492761B (en)
WO (1) WO2008058192A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932595B2 (en) 2008-10-12 2015-01-13 Massachusetts Institute Of Technology Nicotine immunonanotherapeutics
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US9539210B2 (en) 2007-10-12 2017-01-10 Massachusetts Institute Of Technology Vaccine nanotechnology

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
EP1745802A1 (en) * 2005-07-20 2007-01-24 Kreatech Biotechnology B.V. Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
ES2547481T3 (en) 2006-11-08 2015-10-06 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
CA2702305C (en) * 2007-03-30 2015-07-21 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
CN101784192B (en) * 2007-06-26 2015-03-18 约翰·霍普金斯大学 Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA), Biological Evaluation and Use as Imaging Reagents
NZ600085A (en) 2007-08-17 2013-12-20 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
RU2498798C2 (en) 2008-01-09 2013-11-20 Моликьюлар Инсайт Фармасьютикалз, Инк. Carbonic anhydrase ix inhibitors
JP6363320B2 (en) 2008-06-16 2018-07-25 ファイザー・インク Drug-loaded polymer nanoparticles and methods for producing and using the same
PL2285350T3 (en) * 2008-06-16 2018-03-30 Pfizer Inc. Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles
US8613951B2 (en) * 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
US8318211B2 (en) 2008-06-16 2012-11-27 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
HUE059436T2 (en) * 2008-08-01 2022-11-28 Univ Johns Hopkins Psma-binding agents and uses thereof
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
HUE030681T2 (en) * 2008-12-05 2017-05-29 Molecular Insight Pharm Inc Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma
EP2706057B1 (en) 2008-12-05 2016-04-20 Molecular Insight Pharmaceuticals, Inc. Bis(imidazolyl)compounds and radionuclide complexes
US8211402B2 (en) 2008-12-05 2012-07-03 Molecular Insight Pharmaceuticals, Inc. CA-IX specific radiopharmaceuticals for the treatment and imaging of cancer
US8563041B2 (en) * 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (en) * 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド Long-circulating nanoparticles for sustained release of therapeutic agents
US20120183847A1 (en) 2009-05-19 2012-07-19 Aic Blab Composite current collector and methods therefor
BR112012000209B8 (en) 2009-06-15 2021-07-27 Molecular Insight Pharm Inc glutamic acid heterodimers and their preparation processes
US12083191B2 (en) 2009-10-19 2024-09-10 Case Western Reserve University Composition and methods for imaging cells
CN102596403A (en) * 2009-10-30 2012-07-18 住友大阪水泥股份有限公司 Exhaust cleaner for internal combustion engine
BR112012016021A8 (en) 2009-12-11 2018-06-12 Bind Biosciences Inc STABLE FORMULATIONS FOR LYOPHILIZATION OF THERAPEUTIC PARTICLES
US9295649B2 (en) 2009-12-15 2016-03-29 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
EP2338892A1 (en) 2009-12-18 2011-06-29 Bayer Schering Pharma Aktiengesellschaft Prostate specific membrane antigen inhibitors
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
JP2011206049A (en) * 2010-03-08 2011-10-20 Sumio Sugano Necrosis marker and use thereof
US10363309B2 (en) 2011-02-04 2019-07-30 Case Western Reserve University Targeted nanoparticle conjugates
US8926944B2 (en) * 2011-08-05 2015-01-06 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
US9120837B2 (en) 2012-01-06 2015-09-01 Molecular Insight Pharmaceuticals Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX
MX356097B (en) 2012-09-17 2018-05-14 Pfizer Inc Star Process for preparing therapeutic nanoparticles.
KR102575825B1 (en) * 2012-11-15 2023-09-06 엔도사이트, 인코포레이티드 Conjugates for treating diseases caused by psma expressing cells
WO2014110372A1 (en) * 2013-01-14 2014-07-17 Molecular Insight Pharmaceuticals Triazine based radiopharmaceuticals and radioimaging agents
EP2958596B1 (en) * 2013-02-15 2019-12-04 Case Western Reserve University Psma ligands and uses thereof
US12465651B2 (en) 2013-02-15 2025-11-11 Case Western Reserve University Photodynamic therapy composition
US11975074B2 (en) 2013-02-15 2024-05-07 Case Western Reserve University Photodynamic therapy composition
US10207005B2 (en) 2013-02-15 2019-02-19 Case Western Reserve University Photodynamic therapy composition
US10434194B2 (en) 2013-06-20 2019-10-08 Case Western Reserve University PSMA targeted nanobubbles for diagnostic and therapeutic applications
WO2015057692A1 (en) * 2013-10-14 2015-04-23 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
JP6908964B2 (en) * 2013-10-18 2021-07-28 ピーエスエムエー ディベロップメント カンパニー，エルエルシー Combination therapy with PSMA ligand conjugate
US20150110814A1 (en) * 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
EA037778B1 (en) 2013-10-18 2021-05-20 Дойчес Кребсфоршунгсцентрум Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
KR102457827B1 (en) 2013-11-14 2022-10-24 엔도사이트, 인코포레이티드 Compounds for positron emission tomography
US20150147339A1 (en) 2013-11-15 2015-05-28 Psma Development Company, Llc Biomarkers for psma targeted therapy for prostate cancer
PT3116547T (en) 2014-03-14 2019-07-25 Pfizer Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
WO2016030329A1 (en) * 2014-08-24 2016-03-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer
EP3193914B1 (en) 2014-09-08 2021-01-20 Molecular Insight Pharmaceuticals, Inc. Organ protection in psma-targeted radionuclide therapy of prostate cancer
US10736974B2 (en) 2014-10-22 2020-08-11 The Johns Hopkins University Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US20180338910A1 (en) * 2015-01-09 2018-11-29 The Johns Hopkins University Intranasal administration of glutamate carboxypeptidase (gcp-ii) inhibitors
KR102233726B1 (en) 2015-09-30 2021-03-31 도이체스 크렙스포르슝스첸트룸 18F-tagged inhibitor of prostate specific membrane antigen (PSMA) and its use as a contrast agent for prostate cancer
KR101639599B1 (en) 2015-11-09 2016-07-14 서울대학교산학협력단 Peptide thiourea derivatives, their radioisotope labeled compounds and pharmaceutical composition for treatment or diagnosis of prostate cancer comprising the same as an active ingredient
US10882871B2 (en) 2016-01-10 2021-01-05 British Columbia Cancer Agency Branch 18/19F-labelled compounds which target the prostate specific membrane antigen
WO2017184231A1 (en) 2016-04-20 2017-10-26 Dow Corning Corporation Lithium alkylsiliconate composition, coating, and method of making same
FI127538B (en) 2016-06-22 2018-08-31 Dextech Medical Ab MODIFIED DEXTRAN CONJUGATES
EP4520745A3 (en) * 2016-06-23 2025-05-14 Cornell University Double targeted constructs to affect tumor kill
US10806806B2 (en) 2016-06-23 2020-10-20 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
CN109843338B (en) * 2016-06-28 2022-12-13 康奈尔大学 Containing PSMA inhibitors 18 F-labelled triazoles
CN117563022A (en) 2017-04-05 2024-02-20 康奈尔大学 Trifunctional constructs with tunable pharmacokinetics for imaging and anti-tumor therapy
EP3634474A1 (en) * 2017-06-09 2020-04-15 GEMoaB Monoclonals GmbH Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders
PT3498308T (en) 2017-12-13 2025-01-27 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
JP7503495B2 (en) 2018-02-06 2024-06-20 ザ・ジョンズ・ホプキンス・ユニバーシティ PSMA-targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
MX2020010813A (en) 2018-04-17 2021-01-08 Endocyte Inc Methods of treating cancer.
CN113166087B (en) * 2018-09-21 2024-05-10 恩多塞特公司 Screening agent and use thereof
WO2020077259A1 (en) 2018-10-11 2020-04-16 Progenics Pharmaceuticals, Inc Combination therapy for treating metastatic prostate cancer
RU2697519C1 (en) * 2018-10-15 2019-08-15 Общество с ограниченной ответственностью "Изварино Фарма" Peptide agent comprising a psma-binding ligand based on a urea derivative, a method for production thereof and use thereof for preparing a conjugate with a drug and diagnostic agent
KR102403970B1 (en) * 2018-12-27 2022-05-31 (주)퓨쳐켐 Carboxylic acid-having compounds for PSMA-targeting and use thereof
EP3911336A4 (en) 2019-01-18 2023-05-10 Case Western Reserve University PSMA LIGAND-TARGETED COMPOUNDS AND THEIR USES
SG11202108109RA (en) * 2019-01-30 2021-08-30 Univ Muenchen Tech Psma binding dual mode radiotracer and therapeutic
US12472272B2 (en) 2019-04-17 2025-11-18 Provincial Health Services Authority Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer
CN114096264B (en) 2019-05-20 2025-03-14 因多塞特股份有限公司 Method for preparing PSMA conjugates
CN119431260A (en) 2019-06-21 2025-02-14 省卫生服务机构 Radiolabeled compounds targeting prostate-specific membrane antigen
KR102269315B1 (en) 2019-10-24 2021-06-24 서울대학교산학협력단 A radiolabeled compound for imaging or therapy of prostate cancer
KR102732147B1 (en) * 2019-11-21 2024-11-20 페로노바 피티와이 리미티드 Magnetic Tracker Composition
GB2610074B (en) * 2020-03-26 2024-07-10 Marigdalia Kaleth Ramirez Fort Ultraviolet radiation treatments
WO2021202376A1 (en) 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
CN111548305B (en) * 2020-05-12 2021-08-31 北京师范大学 A kind of quinoline compound that can be used for targeting PSMA and preparation method thereof
CN112209970B (en) * 2020-10-21 2021-10-29 北京师范大学 A kind of preparation method and application of technetium-99m labeling isonitrile-containing glutamic acid-urea derivative
EP4244216A1 (en) 2020-11-12 2023-09-20 ABX Advanced Biochemical Compounds GmbH Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks
CA3237590A1 (en) 2021-11-09 2023-05-08 James Basilion Psma targeted conjugate compounds and uses thereof
IL321958A (en) 2023-01-10 2025-09-01 Sun Pharma Advanced Res Co Ltd Ligand-drug conjugates
CN120265331A (en) 2023-07-31 2025-07-04 美国锔责任有限公司 [177Lu] Lutetium-PSMA I&T compositions and dosimetry, kits, preparation methods, and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528499B1 (en) * 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
US20040054190A1 (en) * 2002-01-10 2004-03-18 Johns Hopkins University Imaging agents and methods of imaging NAALADase or PSMA
US20060198785A1 (en) * 2003-04-15 2006-09-07 Santos Isabel R Bifunctional tridentate pyrazolyl containing ligands for re and tc tricarbonyl complexes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3527789A (en) * 1967-10-06 1970-09-08 Shell Oil Co Production of poly(lower)alkyl alkenepolycarboxylates
JP2608550B2 (en) * 1986-10-17 1997-05-07 株式会社 片山化学工業研究所 Corrosion protection method for soft water boiler
US4888136A (en) * 1988-05-02 1989-12-19 Witco Corporation New flame retardant compositions of matter and cellulosic products containing same
TW353663B (en) * 1991-04-06 1999-03-01 Hoechst Ag Process for the preparation of phosphorus-containing L-amino acids, their derivatives and intermediates for this process
IT1270260B (en) * 1994-06-21 1997-04-29 Zambon Spa PHOSPHONIC ACID DERIVATIVES FOR METALLOPEPTIDASE INHIBITIVE ACTIVITIES
US6011021A (en) 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5795877A (en) * 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US6071965A (en) 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
EP1005348A1 (en) 1996-09-27 2000-06-07 Guilford Pharmaceuticals Inc. Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
US5962521A (en) 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
US6479470B1 (en) * 1999-04-28 2002-11-12 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALAdase
US6228888B1 (en) 1999-07-01 2001-05-08 Guilford Pharmaceuticals Inc. Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
AU2003213819C1 (en) * 2002-03-11 2010-03-04 Molecular Insight Pharmaceuticals, Inc. Technetium-dipyridine complexes, and methods of use thereof
US20060166208A1 (en) * 2002-11-07 2006-07-27 Hogg Philip J Induction of the mitochondrial permeability transition
CA2522326C (en) * 2003-04-15 2012-09-18 Mallinckrodt Inc. Bifunctional tridentate pyrazolyl containing ligands for re, tc and mn tricarbonyl complexes
US7741510B2 (en) * 2005-01-13 2010-06-22 E. I. Du Pont De Nemours And Company Rheology control agents
US20060155021A1 (en) * 2005-01-13 2006-07-13 Lenges Christian P Coating compositions containing rheology control agents
WO2006093991A1 (en) * 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
ES2547481T3 (en) 2006-11-08 2015-10-06 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
CN101784192B (en) * 2007-06-26 2015-03-18 约翰·霍普金斯大学 Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA), Biological Evaluation and Use as Imaging Reagents
NZ600085A (en) * 2007-08-17 2013-12-20 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
EP3964502B1 (en) 2009-03-19 2024-06-12 The Johns Hopkins University Psma-targeting compounds and uses thereof
BR112012000209B8 (en) * 2009-06-15 2021-07-27 Molecular Insight Pharm Inc glutamic acid heterodimers and their preparation processes
US8926944B2 (en) 2011-08-05 2015-01-06 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
EA037778B1 (en) 2013-10-18 2021-05-20 Дойчес Кребсфоршунгсцентрум Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3193914B1 (en) 2014-09-08 2021-01-20 Molecular Insight Pharmaceuticals, Inc. Organ protection in psma-targeted radionuclide therapy of prostate cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528499B1 (en) * 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
US20040054190A1 (en) * 2002-01-10 2004-03-18 Johns Hopkins University Imaging agents and methods of imaging NAALADase or PSMA
US20060198785A1 (en) * 2003-04-15 2006-09-07 Santos Isabel R Bifunctional tridentate pyrazolyl containing ligands for re and tc tricarbonyl complexes

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US9539210B2 (en) 2007-10-12 2017-01-10 Massachusetts Institute Of Technology Vaccine nanotechnology
US8932595B2 (en) 2008-10-12 2015-01-13 Massachusetts Institute Of Technology Nicotine immunonanotherapeutics

Also Published As

Publication number Publication date
ES2926912T3 (en) 2022-10-31
US20210246103A1 (en) 2021-08-12
JP5606737B2 (en) 2014-10-15
US10647666B2 (en) 2020-05-12
EP2097111B1 (en) 2015-07-15
SI2097111T1 (en) 2016-02-29
HUE026216T2 (en) 2016-05-30
TWI492761B (en) 2015-07-21
HUE059645T2 (en) 2022-12-28
CN101778910A (en) 2010-07-14
HK1257260A1 (en) 2019-10-18
ES2684322T3 (en) 2018-10-02
PT2097111E (en) 2015-11-03
DK2097111T3 (en) 2015-08-24
CN103922998A (en) 2014-07-16
US8487129B2 (en) 2013-07-16
CY1116610T1 (en) 2017-03-15
EP2942065A1 (en) 2015-11-11
BRPI0718700B1 (en) 2023-10-10
US20210070696A1 (en) 2021-03-11
EP2097111A2 (en) 2009-09-09
US9309193B2 (en) 2016-04-12
CA2669127A1 (en) 2008-05-15
CN101778910B (en) 2014-05-28
HUE039199T2 (en) 2018-12-28
US20170044098A1 (en) 2017-02-16
EP2942065B1 (en) 2018-06-27
US20160279235A1 (en) 2016-09-29
PL2942065T3 (en) 2018-11-30
PL2097111T3 (en) 2016-01-29
US20080193381A1 (en) 2008-08-14
US20230095637A1 (en) 2023-03-30
US10640461B2 (en) 2020-05-05
PL3699162T3 (en) 2022-10-31
JP5936659B2 (en) 2016-06-22
BRPI0718700B8 (en) 2023-11-07
US20120269726A1 (en) 2012-10-25
ES2847275T3 (en) 2021-08-02
AU2007316391A1 (en) 2008-05-15
EP3699162A1 (en) 2020-08-26
US20190276393A1 (en) 2019-09-12
US20210070695A1 (en) 2021-03-11
JP2010509358A (en) 2010-03-25
ES2547481T3 (en) 2015-10-06
HK1200164A1 (en) 2015-07-31
JP2015044807A (en) 2015-03-12
BRPI0718700A2 (en) 2013-12-31
EP2097111A4 (en) 2012-07-11
TW200836765A (en) 2008-09-16
US20120208988A1 (en) 2012-08-16
WO2008058192A2 (en) 2008-05-15
CA2669127C (en) 2016-09-13
EP3699162B1 (en) 2022-06-29
EP3335736A1 (en) 2018-06-20
US9878980B2 (en) 2018-01-30
US20180111895A1 (en) 2018-04-26
EP3335736B1 (en) 2020-12-30
PT3699162T (en) 2022-10-11
EP4023624A1 (en) 2022-07-06
US10131627B2 (en) 2018-11-20

Similar Documents

Publication Publication Date Title
WO2008058192A3 (en) Heterodimers of glutamic acid
WO2008057855A3 (en) Heterocyclic compounds as modulators of glucocorticoid receptor, ap-i, and/or np-kappa-b activity
WO2006122806A3 (en) 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors
EP2826472A3 (en) Telomerase activating compounds and their use
WO2008108386A1 (en) Pharmaceutical composition
PE20081806A1 (en) IMIDAZO- AND SUBSTITUTE TRIAZOLOPYRIMIDINES
FI4159217T3 (en) COMBINATION OF MEK INHIBITOR AND B-RAF INHIBITOR
BRPI0712163A2 (en) compound and antimicrobial agent
WO2010066684A3 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
MX2010001020A (en) Organic compounds.
ATE541830T1 (en) AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICAL USE THEREOF
CY1114520T1 (en) INDOLISIN PRODUCER AND USE FOR MEDICAL PURPOSES
BRPI0905687A2 (en) "compound of formula i or i ', pharmaceutical composition, method of treating a patient with a disease, use of the compound"
MX337396B (en) Method of treating polycystic kidney diseases with ceramide derivatives.
WO2006023515A3 (en) Novel thiazole inhibitors of fructose 1,6-bisphosphatase
ATE471323T1 (en) PURINE DERIVATIVES AS ANTAGONISTS AT PURINERGIC RECEPTORS
DK2041133T3 (en) Derivatives of imadazole [1,2-A] pyridine-2-carboxamides, their preparation and their use in therapeutics
MX2010001170A (en) Imidazolone derivatives, preparation method thereof and biological use of same.
BRPI0418181A (en) use of substituted 2-aminotetralines to prevent treatment of morbus parkinson
WO2006060809A3 (en) Methods of using [3.2.0] heterocyclic compounds and analogs thereof
IL276711B2 (en) Arginase inhibitors and methods of using them
CY1118033T1 (en) Fluorinated arylalkylaminocarboxamide derivatives
HRP20080598T3 (en) Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
WO2007125398A3 (en) : sulfonamide compounds as antagonists of the n-type calcium channel
WO2007024843A3 (en) Pyrimidinyl-pyrazole inhibitors of aurora kinases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780049490.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07844938

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007316391

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2669127

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009536459

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1787/KOLNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007316391

Country of ref document: AU

Date of ref document: 20071107

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007844938

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0718700

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090508